Introduction:
The landscape of incretin-based therapies has expanded far beyond the first-generation GLP-1 receptor agonists. Regulatory submissions for GLP-2 and Dual GIP/GLP-1 agonist characterization for ANDA now demand a scientifically rigorous, class-specific approach that cannot simply be copied from the GLP-1 analog playbook. Similar analytical challenges have been observed in the field of Analytical Characterization of GLP-1 Peptide Drugs, where comprehensive structural and functional assessment is required to establish pharmaceutical equivalence and support regulatory submissions. As tirzepatide (a dual GIP/GLP-1 agonist) and teduglutide (a GLP-2 analog) move toward potential generic competition, the pharmaceutical industry must address a fundamental question: does GLP-2 and Dual GIP/GLP-1 agonist characterization for ANDA mirror what regulators expect for GLP-1 analogs, or does each class demand its own unique analytical blueprint?
This article examines FDA’s characterization expectations across these therapeutic classes, identifies key similarities and critical divergences, and illustrates how manufacturers can build a scientifically defensible analytical package for complex peptide ANDA submissions.
Summary:
- GLP-2 analogs and dual GIP/GLP-1 receptor agonists are peptide or peptide-mimetic drugs with distinct receptor targets and molecular complexity, requiring thorough physicochemical, biological, and immunochemical characterization for ANDA approval.
- While FDA’s reference-listed drug (RLD) comparison framework applies broadly, the specific analytical tests differ based on each drug class’s mechanism, formulation, and molecular architecture.
- GLP-1 analogs (e.g., semaglutide, liraglutide) set a high analytical precedent; GLP-2 and dual agonists introduce new characterization challenges including receptor selectivity, conformation, and aggregation behavior.
- Key analytical domains for GLP-2 and Dual GIP/GLP-1 ANDA submissions include identity, purity, potency, higher-order structure, immunogenicity risk, and drug product performance testing.
- ResolveMass Laboratories Inc. offers integrated CRO/CDMO services — from physicochemical characterization to bioanalytical method development — to support complex peptide ANDA filing strategies.
1: Understanding the Regulatory Framework for Complex Peptide ANDAs
The FDA classifies GLP-1 analogs, GLP-2 analogs, and dual GIP/GLP-1 agonists as complex drug substances under the Federal Food, Drug, and Cosmetic Act. ANDA applicants must demonstrate that the proposed product is pharmaceutically equivalent — same active ingredient, dosage form, route of administration, and strength — and bioequivalent to the RLD.
For complex peptides, this means the characterization package must go beyond traditional small molecule approaches. FDA guidance documents — including the draft guidance on complex drug substances and product-specific guidances (PSGs) — outline that:
- Physicochemical identity and structural equivalence must be rigorously established.
Regulatory expectations for peptide therapeutics continue to evolve, particularly for incretin-based drugs. Sponsors can reference current Regulatory Requirements for GLP-1 Peptide Characterization and detailed discussions on GLP-1 Peptide Characterization Regulatory Requirements to better understand FDA expectations regarding structural sameness, impurity control, and analytical comparability. - Impurity profiles must match or be acceptable relative to the RLD.
- Bioequivalence may require pharmacokinetic studies supported by validated bioanalytical methods.
- Higher-order structural attributes (secondary, tertiary, and quaternary structure) are increasingly expected as part of the characterization evidence.
Importantly, the specific battery of tests and acceptance criteria are not identical across GLP-1 analogs, GLP-2 analogs, and dual agonists — each drug’s molecular features and pharmacological mechanism drive the characterization strategy.
2: GLP-1 Analog Characterization for ANDA: Establishing the Benchmark
GLP-1 analogs such as semaglutide and liraglutide have established a high analytical bar for complex peptide ANDA submissions. Their characterization packages typically include:
| Characterization Domain | Typical Analytical Methods | Regulatory Rationale |
|---|---|---|
| Primary Structure / Identity | LC-MS, peptide mapping, amino acid analysis | Confirm sequence fidelity to RLD |
| Purity & Related Substances | HPLC, UHPLC, CE, size exclusion | Detect degradants, truncated forms |
| Higher-Order Structure | CD, NMR, HDX-MS, FTIR | Structural equivalence to RLD |
| Potency / Biological Activity | GLP-1R cell-based cAMP assay | Functional equivalence |
| Fatty Acid Modification (Semaglutide) | LC-MS, NMR | Modification critical to half-life |
| Aggregation / Particle Analysis | DLS, SEC-MALS, MFI | Safety and stability indicator |
| Formulation & Drug Product Testing | pH, osmolality, injectability, container closure | Pharmaceutical equivalence |
At the core of these characterization programs is comprehensive Peptide Sequencing of GLP-1 Peptide combined with advanced LC-MS Characterization of GLP-1 Peptides. These methodologies establish sequence fidelity, identify critical modifications, and provide the analytical foundation necessary for demonstrating equivalence to the reference listed drug. For lipidated molecules such as semaglutide, dedicated Semaglutide Peptide Mapping studies are often required to verify the site-specific attachment of fatty acid moieties and confirm molecular integrity.
These tests reflect FDA’s expectation that the complete physicochemical and biological fingerprint of the RLD must be characterized and replicated. This benchmark informs — but does not fully define — what regulators will expect from GLP-2 and dual agonist programs.
3: GLP-2 Analog Characterization for ANDA: What Is Different?
Molecular Architecture and Receptor Specificity
GLP-2 analogs, such as teduglutide, act selectively on the GLP-2 receptor — a distinct GPCR from the GLP-1 receptor — to promote intestinal epithelial growth and mucosal integrity. This receptor selectivity is a critical quality attribute (CQA) that must be confirmed analytically and, where possible, functionally.
Key differences in the GLP-2 characterization strategy include:
- Receptor Selectivity Confirmation: Unlike GLP-1 analogs where off-target GIP receptor activity is generally not a concern, GLP-2 analogs must demonstrate specificity for the GLP-2R and minimal cross-reactivity with GLP-1R or GIP-R, particularly if any structural modifications are present.
- Sequence and Modification Analysis: Teduglutide carries a specific N-terminal modification (Gly2 substitution of Ala2) that confers DPP-4 resistance. The integrity and fidelity of this modification must be confirmed by peptide mapping and LC-MS/MS.
- Intestinotrophic Bioassay: A GLP-2R-specific cell-based potency assay is required to demonstrate functional equivalence. Standard GLP-1 cAMP assays are not applicable.
- Immunogenicity Risk Assessment: Given the peptide’s role in intestinal growth promotion, an immunogenicity risk assessment — including T-cell epitope prediction and ADA assay development — may be expected.
Advanced Peptide Mapping of GLP-1 Peptides and GLP-1 Enzymatic Digestion Mapping strategies provide valuable frameworks for confirming sequence modifications, enzymatic cleavage patterns, and site-specific structural attributes in complex peptide therapeutics. In addition, GLP-1 Sequence Variant Analysis can help identify low-level variants that may influence biological activity, stability, or immunogenicity risk.
Formulation-Specific Considerations for GLP-2 ANDAs
Teduglutide is supplied as a lyophilized powder for reconstitution, introducing a unique set of drug product characterization requirements compared to pre-filled GLP-1 analog injectors:
- Reconstituted solution characterization: pH, clarity, subvisible particle analysis, and time-to-dissolution.
- Lyophilized cake analysis: moisture content, cake morphology, residual solvent testing.
- Excipient compatibility: assessment of mannitol and sodium phosphate buffer components on peptide stability.
4: Dual GIP/GLP-1 Agonist Characterization for ANDA: The Most Complex Case
Why Dual Agonists Present Unique Analytical Challenges
Dual GIP/GLP-1 receptor agonists — of which tirzepatide is the paradigm example — are synthetic peptides engineered to co-activate both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). This dual pharmacology introduces multi-dimensional characterization demands that exceed those for mono-selective GLP-1 or GLP-2 analogs.
Modern HRMS Peptide Mapping for GLP-1 approaches provide the mass accuracy necessary to characterize linker chemistry, lipid conjugation sites, and subtle sequence variants in dual agonist molecules. Furthermore, combining GLP-1 Peptide Mapping vs Intact Mass Analysis offers complementary insights into molecular identity, heterogeneity, and structural integrity that cannot be obtained from a single analytical technique alone.
The central analytical challenge is demonstrating that the proposed product retains the precise balance of dual receptor activation that defines the RLD’s therapeutic profile. This requires:
- Dual Receptor Potency Assays: Separate, validated cell-based cAMP assays for both GIPR and GLP-1R activity, with acceptance criteria benchmarked against the RLD.
- Selectivity and Off-Target Profiling: Assessment of activity at the GLP-2R and other related GPCRs to confirm that the receptor selectivity profile of the generic matches the RLD.
- Structural Characterization of C20 Fatty Diacid Moiety: Tirzepatide carries a C20 fatty diacid conjugated via a linker to Lys26. Confirmation of this modification — its identity, site specificity, and linker integrity — requires advanced LC-MS/MS peptide mapping.
- Conformation and Self-Assembly: The fatty acid modification drives albumin binding and potentially peptide self-assembly in formulation. Analytical tools such as native MS, HDX-MS, and SEC-MALS are essential.
- Aggregation Profiling: Given the amphiphilic character of dual agonists, aggregation propensity — including soluble oligomers and subvisible particles — must be characterized under stressed and real-time conditions.
Because aggregation and degradation pathways can significantly impact potency and immunogenicity, comprehensive GLP-1 Peptide Stability Analytical Methods should be incorporated into analytical development programs to evaluate formulation-induced changes and long-term product stability.
Comparative Characterization Table: GLP-1 vs GLP-2 vs Dual GIP/GLP-1
| Characterization Domain | GLP-1 Analogs | GLP-2 Analogs | Dual GIP/GLP-1 Agonists |
|---|---|---|---|
| Primary Structure / Identity | Required | Required | Required |
| Purity & Related Substances | Required | Required | Required |
| Receptor Selectivity Assay | GLP-1R specific | GLP-2R specific | Dual GIPR + GLP-1R required |
| Off-Target Receptor Profiling | Generally not required | GLP-1R cross-reactivity check | GLP-2R and other GPCRs |
| Fatty Acid / Lipid Modification | Yes (semaglutide/liraglutide) | No | Yes (C20 diacid, tirzepatide) |
| Higher-Order Structure (CD/HDX) | Required | Required | Required; albumin-bound conformation |
| Aggregation & Particle Analysis | Required | Required | Critical; amphiphile-driven assembly |
| Lyophilization Testing | Not typically applicable | Required (teduglutide) | Not applicable (solution) |
| Immunogenicity Risk Assessment | Standard peptide risk | Growth-promoting peptide risk | Lipidated peptide; elevated risk |
5: Common Characterization Requirements Across All Three Classes
Despite their differences, GLP-1 analogs, GLP-2 analogs, and dual GIP/GLP-1 agonists share a core characterization foundation that any ANDA applicant must address:
- Sequence Confirmation: High-resolution peptide mapping by LC-MS/MS to confirm the complete primary structure, including any post-translational or chemical modifications.
Regulators increasingly expect orthogonal confirmation using Peptide Sequencing of GLP-1 Drugs, advanced GLP-1 Analog Peptide Sequencing Workflow approaches, and, when necessary, De Novo GLP-1 Peptide Sequencing Accuracy studies to verify complex peptide structures. - Purity and Impurity Profiling: Quantitation of process-related impurities, degradation products, and synthesis-related impurities by HPLC and CE methods.
Detailed GLP-1 Peptide Impurity Characterization and GLP-1 Peptide Impurity Sequencing Analysis are often necessary to identify synthesis-related impurities, degradation products, and sequence variants that may impact product quality, safety, and efficacy. Additional GLP-1 Impurity Peptide Mapping studies can localize structural changes and degradation hotspots within the peptide sequence. - Chirality and Stereochemistry: Confirmation of L-amino acid configuration and absence of D-amino acid-containing impurities.
- Disulfide Bond Integrity: Where applicable, confirmation of disulfide bond connectivity by non-reducing peptide mapping.
- Physicochemical Properties: Molecular weight by high-resolution MS, isoelectric point, solubility, and pH-stability profiles.
- Drug Product Performance: Dissolution/release testing, container closure integrity, extractables and leachables from primary packaging.
For structurally constrained peptide therapeutics, analytical approaches commonly employed in Cyclic Peptide Characterization can provide valuable insights into conformational stability, folding behavior, and higher-order structural integrity.
6: Bioanalytical Considerations for Bioequivalence Studies
Bioequivalence studies for complex peptide ANDAs require validated bioanalytical methods capable of selectively measuring the drug in biological matrices. Critically, the assay must distinguish the drug substance from endogenous analogs and from structurally similar therapeutic agents.
For GLP-2 and dual agonist ANDA bioequivalence programs, specific bioanalytical challenges include:
- Endogenous Interference: GLP-1, GLP-2, and GIP are endogenously produced; method selectivity must be rigorously validated against endogenous peptide levels across the relevant patient population.
- PK-Linked Immunogenicity Monitoring: Anti-drug antibody (ADA) assays must be co-validated to confirm that immunogenicity does not confound PK comparisons between test and reference products.
- Method Sensitivity: Subcutaneous peptide formulations often require assays with LLOQ values in the pg/mL range, necessitating LC-MS/MS or highly sensitive immunoassay platforms.
- Metabolite Characterization: Active metabolites or DPP-4 cleavage products must be characterized and, where pharmacologically active, quantified independently.
7: How ResolveMass Laboratories Inc. Supports GLP-2 and Dual GIP/GLP-1 ANDA Programs
ResolveMass Laboratories Inc. is a USFDA-registered Canadian CRO/CDMO with deep expertise in the analytical and bioanalytical characterization of complex peptide drug substances and drug products.As a specialized CRO for GLP-1 Peptide Characterization, ResolveMass Laboratories Inc. provides comprehensive analytical support for complex peptide drug development programs. Our scientists routinely address GLP-1 Peptide Sequencing Challenges using advanced GLP-1 Peptide Sequencing Analytical Techniques the-art mass spectrometry platforms.
Our integrated service offering covers the full spectrum of requirements for GLP-2 and Dual GIP/GLP-1 agonist characterization for ANDA submissions:
- Physicochemical Characterization: LC-MS/MS peptide mapping, amino acid analysis, isoelectric focusing, CD spectroscopy, and DSC for thermal stability profiling.
- Potency and Receptor Selectivity Assays: Development and validation of GLP-1R, GLP-2R, and GIPR cell-based cAMP assays; dual receptor selectivity profiling.
- Higher-Order Structure Analysis: Circular dichroism, dynamic light scattering, HDX-MS, native MS, and SEC-MALS for aggregation and conformation characterization.
- Impurity Profiling and Method Development: ICH-compliant analytical method development and validation for complex peptide matrices.
- Bioanalytical Method Development: LC-MS/MS and immunoassay-based PK assays for subcutaneously administered peptides with complex endogenous backgrounds.
- Immunogenicity Risk Assessment and ADA Assay Development: Tiered ADA screening, confirmatory, and titration assays in compliance with FDA and EMA guidance.
- Regulatory Writing Support: CMC narrative development, analytical comparability reports, and method validation summaries aligned with FDA ANDA expectations.
Our team brings direct experience in peptide characterization programs across injectable formulations, lyophilized products, and modified peptide APIs — precisely the technical landscape that GLP-2 and dual agonist ANDA programs require.
Conclusion:
The answer to whether GLP-2 and Dual GIP/GLP-1 agonist characterization for ANDA mirrors GLP-1 analog requirements is nuanced: the regulatory framework is the same, but the analytical strategy must be precisely tailored to each drug class. GLP-2 analogs demand GLP-2R-specific potency assays, lyophilization testing, and growth-promoting peptide immunogenicity assessment. Dual GIP/GLP-1 agonists require co-validation of dual receptor activity, lipid modification characterization, and elevated scrutiny of aggregation behavior driven by their amphiphilic structure.
\Sponsors seeking external expertise for complex peptide programs can leverage our Outsource GLP-1 Peptide Sequencing Services and GLP-1 Peptide Sequencing CRO Services to support analytical development, characterization, and regulatory submissions. To streamline project initiation, sponsors are encouraged to review our Peptide Characterization CRO Deliverables Checklist and understand the Specifications to Provide When Outsourcing Peptide Characterization CRO before commencing characterization activities.
Generic applicants who apply a one-size-fits-all GLP-1 characterization template to these newer drug classes risk receiving FDA Complete Response Letters citing insufficient scientific justification for the chosen analytical methods. A class-specific, RLD-anchored, scientifically defensible characterization package is not a regulatory luxury — it is the standard that FDA expects and that patients deserve.
ResolveMass Laboratories Inc. is positioned to be your technical partner at every stage of this journey, from early feasibility through ANDA submission and approval.
Frequently Asked Questions:
Yes, GLP-2 analogs generally require the same foundational characterization approach used for GLP-1 analogs in ANDA submissions. This includes confirming amino acid sequence, molecular weight, purity, potency, and impurity profiles. Regulatory agencies expect developers to demonstrate that the active ingredient matches the reference listed drug. However, additional characterization may be needed if the GLP-2 analog contains unique modifications or exhibits distinct degradation pathways. The overall goal is to establish pharmaceutical equivalence through comprehensive analytical data.
GLP-2 and Dual GIP/GLP-1 Agonist Characterization for ANDA refers to the analytical studies performed to demonstrate the identity, quality, purity, potency, and structural integrity of these peptide drugs. The characterization package helps prove that a generic product is equivalent to the reference product. It typically includes mass spectrometry, peptide mapping, impurity profiling, and stability studies. Regulatory agencies use this information to assess product sameness and quality. Robust characterization is a key component of a successful ANDA submission.
Dual GIP/GLP-1 agonists are often more complex because they contain longer peptide sequences, engineered amino acid substitutions, and functional modifications such as lipid conjugation. These features can increase molecular heterogeneity and create additional impurities that must be identified and controlled. Their dual receptor activity also requires a more comprehensive understanding of biological function. As a result, developers often need advanced analytical techniques and more extensive characterization programs. This complexity can increase both development time and regulatory scrutiny.
Mass spectrometry is one of the most important tools used in the characterization of peptide therapeutics. It provides detailed information about molecular weight, amino acid sequence, modifications, impurities, and degradation products. High-resolution mass spectrometry can detect even minor structural differences that may impact product quality. For complex peptides such as GLP-2 analogs and Dual GIP/GLP-1 agonists, mass spectrometry is often essential for demonstrating equivalence to the reference product. It plays a central role in regulatory submissions and quality assessments.
Yes, peptide mapping is considered a critical characterization tool for Dual GIP/GLP-1 agonists. It helps verify the amino acid sequence and confirm that the peptide structure matches the reference product. Peptide mapping can also identify modifications, sequence variants, and degradation products. When combined with mass spectrometry, it provides highly detailed structural information. Regulatory agencies often view peptide mapping as an essential component of demonstrating peptide sameness.
Lipid conjugation can significantly increase the analytical complexity of peptide therapeutics. The attached lipid chain may alter chromatographic behavior, increase molecular heterogeneity, and create additional variants that require characterization. It can also influence stability, potency, and pharmacokinetic properties. Specialized analytical methods are often necessary to confirm the conjugation site and assess related impurities. Thorough characterization of lipid-modified peptides is critical for regulatory acceptance.
Critical Quality Attributes are the measurable properties that ensure a peptide drug meets quality, safety, and efficacy requirements. Common CQAs include sequence identity, molecular weight, purity, potency, impurity profile, aggregation levels, and stability. For modified peptides, conjugation integrity may also be considered a critical attribute. These parameters are evaluated throughout development and manufacturing. Demonstrating control of CQAs is essential for regulatory approval and product consistency.
Reference
- Lindner S, Keim S, Haddadzadegan S, Fernandez Romero O, Zöller K, Stern G, Cesi I, Kafedjiiski K, Bernkop‐Schnürch A. Strategies to improve the lipophilicity of hydrophilic macromolecular drugs. Advanced healthcare materials. 2026 Feb;15(5):e03721.https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adhm.202503721
- Piteau SJ. Studies on the potential utilization of glucose-dependent insulinotropic polypeptide (GIP) in type 1 and type 2 diabetes (Doctoral dissertation, University of British Columbia).https://open.library.ubc.ca/soa/cIRcle/collections/831/items/1.0092523
- Jensen CB. Quantitative evaluation of peptide analogue distribution in mouse tissue using 3D computer modelling.https://orbit.dtu.dk/en/publications/quantitative-evaluation-of-peptide-analogue-distribution-in-mouse/
About the Author
